Keeping America’s lead in biotech depends on fixing what's broken about the policy status quo — and not breaking what works, ...

The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope.

Annalisa (Nalis) Merelli is a contributing writer at STAT focused on boys’ and men’s health. The early 1990s were a watershed moment for female health. In 1990, the Office of Research on Women’s ...

Norton is a health equity and public health scientist, a signer and organizer of the Bethesda Declaration, and an NIH program officer currently on administrative leave. She writes in her personal ...

The first patient I met as a medical student was a middle-aged delivery man and a former track athlete. He was recovering from his second amputation due to uncontrolled type 2 diabetes. When he told ...

You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence ...

How Jeffrey Epstein's friend came back to biotech, probes into the FDA's drug rejections, and other biotech news ...

Boris Nikolic’s career looked to be in tatters after his friendship with Jeffrey Epstein came to light in 2019. But he has ...

The Trump administration push for lower U.S. drug prices helped Astellas secure higher pricing for its new eye medicine in Japan ...

A new nonprofit called Radial is launching with at least $500 million to modernize the scientific process for the AI era.

Epstein's "great friend" returns to biotech, sex differences in suicide, and other health news from Morning Rounds ...

AI agents to perform health care work are everywhere at HIMSS 2026. Experts want to know more about their validation.